Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

PENNVAX-GP

Vaccine (DNA plasmid) · Immune activation, directed at HIV-1 Gag protein, HIV-1 Pol protein and HIV-1 Env protein

Phase 1/2 Most advanced trial (none active)
1 Registered trials

What is PENNVAX-GP?

PENNVAX-GP is a DNA vaccine consisting of circular, double-stranded plasmids encoding synthetic HIV-1 multiclade consensus Gag, Pol, and Env proteins. It is studied in HIV-1 infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine (DNA plasmid)
Targets
HIV-1 Gag protein (antigen), HIV-1 Pol protein (antigen), HIV-1 Env protein (antigen)
Mechanism
Immune activation, directed at HIV-1 Gag protein, HIV-1 Pol protein and HIV-1 Env protein
Therapy area
Infectious disease
In trials of
INO
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03606213 Phase 1/2 HIV-1-infection Completed INO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HIV-1-infection

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.